Class summary at a glance.

Every drug in the TNF Blocker class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $8.57Bcombined across class
Total Rx claims: 973K169K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Adalimumab

Brand: HUMIRA · 973K Part D claims (CY24) · 169K beneficiaries · First FDA approval: 2002-12-31

Brand-only (no generics) 1441 plans require PA

Low NADAC$872.45

→

Avg plan cost$3898.50

Part D spend $8.57B 4× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.